Pfizer's Plan To Establish A $6bn Migraine Franchise
Executive Summary
Pfizer's strategy for building a mega-blockbuster brand around Nurtec ODT involves establishing oral CGRPs as first-line treatment.
You may also be interested in...
AbbVie Broadens Qulipta Migraine Indication As Anti-CGRP Competition Grows
AbbVie’s migraine franchise expanded with US FDA approval of Qulipta for chronic migraine prevention, but its CGRP inhibitors are facing off against a pair of rivals acquired by Pfizer last year.
Keeping Track: Pfizer’s Zavzpret Brings Nasal Delivery To CGRP Antagonists; Ionis/AZ Advance Antisense Eplontersen In ATTR
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Top 5 Deals Of 2022: The Economic Drag On M&A Continues
Many of the same factors that held down large M&A transactions in 2021 carried over to 2022, which saw eight buyouts valued at $2bn+, headlined by Amgen’s $27.8bn purchase of Horizon.